Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Open in API
Filings indexed 1,392 across all filing types
Latest filing 2017-06-23 Director's Dealing
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2017-06-23 English
PRIMARY DOCUMENT
Director's Dealing
2017-06-10 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 31, 2017. It announces Ligand Pharmaceuticals' entry into a material definitive agreement, specifically a royalty agreement and an amended interest purchase agreement. The content focuses on the description of these agreements, their terms, and related disclosures. There are no financial statements or detailed financial performance data included, only a narrative about the agreements and forward-looking statements. The document also references that the full agreements will be filed later with the 10-Q report. This type of filing is a regulatory announcement about a material contract, which fits the category of a Regulatory Filing (RNS) rather than a full financial report or other specific categories like M&A or Capital Update. Therefore, the appropriate classification is Regulatory Filings (RNS).
2017-05-31 English
4
Director's Dealing
2017-05-30 English
PRIMARY DOCUMENT
Director's Dealing
2017-05-27 English
PRIMARY DOCUMENT
Director's Dealing
2017-05-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.